Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
252. lappuse
... percent aqueous solution . Adults and children 12 years of age and over : 2 or 3 drops or sprays in each nostril not more often than every 4 hours . Chil- dren 6 to under 12 years of age ( with adult supervision ) : 1 or 2 drops or ...
... percent aqueous solution . Adults and children 12 years of age and over : 2 or 3 drops or sprays in each nostril not more often than every 4 hours . Chil- dren 6 to under 12 years of age ( with adult supervision ) : 1 or 2 drops or ...
253. lappuse
... percent aqueous solution . Adults and children 6 to under 12 years of age ( with adult supervision ) : 2 or 3 drops or sprays in each nostril not more often than every 10 to 12 hours . Do not exceed 2 doses in any 24 - hour period ...
... percent aqueous solution . Adults and children 6 to under 12 years of age ( with adult supervision ) : 2 or 3 drops or sprays in each nostril not more often than every 10 to 12 hours . Do not exceed 2 doses in any 24 - hour period ...
257. lappuse
... percent . ( c ) Dibucaine 0.25 to 1 percent . ( d ) Dibucaine hydrochloride 0.25 to 1 percent . ( e ) Dyclonine hydrochloride 0.5 to 1 percent . ( f ) Lidocaine 2 to 5 percent . ( g ) Pramoxine hydrochloride 1 per- cent . ( h ) ...
... percent . ( c ) Dibucaine 0.25 to 1 percent . ( d ) Dibucaine hydrochloride 0.25 to 1 percent . ( e ) Dyclonine hydrochloride 0.5 to 1 percent . ( f ) Lidocaine 2 to 5 percent . ( g ) Pramoxine hydrochloride 1 per- cent . ( h ) ...
258. lappuse
... percent . ( c ) Epinephrine hydrochloride 0.005 to 0.01 percent . ( d ) Phenylephrine hydrochloride 0.25 percent . § 346.14 Protectant active ingredients . ( a ) The following active ingredients may be used as the sole protectant ac ...
... percent . ( c ) Epinephrine hydrochloride 0.005 to 0.01 percent . ( d ) Phenylephrine hydrochloride 0.25 percent . § 346.14 Protectant active ingredients . ( a ) The following active ingredients may be used as the sole protectant ac ...
266. lappuse
... percent . § 349.12 Ophthalmic demulcents . The active ingredients of the product consist of any of the following ... percent . ( 2 ) Hydroxyethyl cellulose , 0.2 to 2.5 percent . ( 3 ) Hydroxypropyl methylcellulose , 0.2 to 2.5 percent ...
... percent . § 349.12 Ophthalmic demulcents . The active ingredients of the product consist of any of the following ... percent . ( 2 ) Hydroxyethyl cellulose , 0.2 to 2.5 percent . ( 3 ) Hydroxypropyl methylcellulose , 0.2 to 2.5 percent ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning